Vaxxinity Reports Fourth Quarter and Full-Year 2023 : vimars

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...

Related Keywords

Portugal , Lisbon , Lisboa , University Of Central Florida , Florida , United States , University Of Florida , Boston , Massachusetts , Mark Joinnides , Exchange Commission On , Journal Of Lipid Research , Nasdaq , Vaxxinity Inc , Translational Research In Neurodegenerative Disease , University Of Florida Center , Michaelj Fox Foundation , Recent Clinical Pipeline , Syn Seed Amplification Assay , Mayo Clinic , Chief Scientific Officer , Vaccines Summit , Recent Corporate , Central Florida , Translational Research , Neurodegenerative Disease , Year End , Private Securities Litigation Reform Act , Annual Report , Exchange Commission , Nasdaq Vaxx , Vaxxinity , Nc ,